Amal Abdul‐Hafez

728 total citations
20 papers, 595 citations indexed

About

Amal Abdul‐Hafez is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Surgery. According to data from OpenAlex, Amal Abdul‐Hafez has authored 20 papers receiving a total of 595 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 5 papers in Molecular Biology and 4 papers in Surgery. Recurrent topics in Amal Abdul‐Hafez's work include Pulmonary Hypertension Research and Treatments (10 papers), Neonatal Respiratory Health Research (8 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (5 papers). Amal Abdul‐Hafez is often cited by papers focused on Pulmonary Hypertension Research and Treatments (10 papers), Neonatal Respiratory Health Research (8 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (5 papers). Amal Abdul‐Hafez collaborates with scholars based in United States, Egypt and Spain. Amal Abdul‐Hafez's co-authors include Bruce D. Uhal, María Molina‐Molina, Xiaopeng Li, A. Xaubet, Xu Gao, Xiaopeng Li, Ruijie Shu, Anna Serrano‐Mollar, José Ramírez and Vinh Dang and has published in prestigious journals such as The FASEB Journal, International Journal of Molecular Sciences and European Respiratory Journal.

In The Last Decade

Amal Abdul‐Hafez

20 papers receiving 590 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amal Abdul‐Hafez United States 12 307 138 133 121 70 20 595
Alicia N. Rizzo United States 13 154 0.5× 32 0.2× 40 0.3× 137 1.1× 36 0.5× 25 480
Metin Özgen Türkiye 14 80 0.3× 52 0.4× 42 0.3× 209 1.7× 118 1.7× 59 690
Diana Gallagher United States 7 336 1.1× 135 1.0× 36 0.3× 234 1.9× 76 1.1× 14 774
Myoung Ju Koh South Korea 9 51 0.2× 54 0.4× 38 0.3× 78 0.6× 59 0.8× 14 412
Susanna Fiorelli Italy 11 51 0.2× 87 0.6× 122 0.9× 146 1.2× 78 1.1× 26 471
Carlos Bueno‐Betí Spain 18 133 0.4× 268 1.9× 28 0.2× 233 1.9× 37 0.5× 25 617
Rodrigo A. Fraga‐Silva Switzerland 14 296 1.0× 189 1.4× 23 0.2× 72 0.6× 174 2.5× 27 575
Renqiang Yang China 13 62 0.2× 142 1.0× 18 0.1× 279 2.3× 76 1.1× 40 636
Ibraheem M. Rajab United States 11 65 0.2× 24 0.2× 64 0.5× 116 1.0× 74 1.1× 16 501
Saskia N. van der Crabben Netherlands 10 54 0.2× 133 1.0× 17 0.1× 183 1.5× 53 0.8× 34 626

Countries citing papers authored by Amal Abdul‐Hafez

Since Specialization
Citations

This map shows the geographic impact of Amal Abdul‐Hafez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amal Abdul‐Hafez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amal Abdul‐Hafez more than expected).

Fields of papers citing papers by Amal Abdul‐Hafez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amal Abdul‐Hafez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amal Abdul‐Hafez. The network helps show where Amal Abdul‐Hafez may publish in the future.

Co-authorship network of co-authors of Amal Abdul‐Hafez

This figure shows the co-authorship network connecting the top 25 collaborators of Amal Abdul‐Hafez. A scholar is included among the top collaborators of Amal Abdul‐Hafez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amal Abdul‐Hafez. Amal Abdul‐Hafez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Abdul‐Hafez, Amal, et al.. (2024). Small Extracellular Vesicles Derived from Cord Blood Plasma and Placental Mesenchymal Stem Cells Attenuate Acute Lung Injury Induced by Lipopolysaccharide (LPS). International Journal of Molecular Sciences. 26(1). 75–75. 2 indexed citations
4.
Omar, Said, et al.. (2022). Stem-Cell Therapy for Bronchopulmonary Dysplasia (BPD) in Newborns. Cells. 11(8). 1275–1275. 34 indexed citations
5.
Abdul‐Hafez, Amal, et al.. (2021). Regulation of ACE-2 enzyme by hyperoxia in lung epithelial cells by post-translational modification. PubMed. 8(2). 47–52. 6 indexed citations
6.
Abdul‐Hafez, Amal, et al.. (2021). Angiotensin Converting Enzyme-2 (ACE-2) role in disease and future in research. PubMed. 8(2). 54–60. 3 indexed citations
7.
8.
Abdul‐Hafez, Amal, et al.. (2019). Activation of mas restores hyperoxia-induced loss of lung epithelial barrier function through inhibition of apoptosis. PubMed. 6(3). 58–62. 8 indexed citations
9.
Uhal, Bruce D., et al.. (2018). The renin angiotensin system in liver and lung: impact and therapeutic potential in organ fibrosis. PubMed. 5(1). 24 indexed citations
10.
Abdul‐Hafez, Amal, et al.. (2017). EVIDENCE FOR ACE‐2 UBIQUITINATION AND PROTEASOMAL PROCESSING IN LUNG EPITHELIUM. The FASEB Journal. 31(S1). 1 indexed citations
11.
Nguyen, Hang Thi Thu, et al.. (2016). Prior hypoxia prevents downregulation of ACE-2 by hyperoxia in fetal human lung fibroblasts. Experimental Lung Research. 42(3). 121–130. 18 indexed citations
12.
Uhal, Bruce D., et al.. (2012). Cell cycle dependence of ACE-2 explains downregulation in idiopathic pulmonary fibrosis. European Respiratory Journal. 42(1). 198–210. 50 indexed citations
13.
Uhal, Bruce D., et al.. (2012). Angiotensinogen Gene Transcription in Pulmonary Fibrosis. PubMed. 2012. 1–8. 13 indexed citations
14.
Uhal, Bruce D., et al.. (2011). Regulation of alveolar epithelial cell survival by the ACE-2/angiotensin 1–7/Mas axis. American Journal of Physiology-Lung Cellular and Molecular Physiology. 301(3). L269–L274. 96 indexed citations
15.
Abdul‐Hafez, Amal, Ruijie Shu, & Bruce D. Uhal. (2009). JunD and HIF‐1α mediate transcriptional activation of angiotensinogen by TGF‐β1 in human lung fibroblasts. The FASEB Journal. 23(6). 1655–1662. 37 indexed citations
16.
Molina‐Molina, María, Antoni Xaubet, Amal Abdul‐Hafez, et al.. (2008). Angiotensinogen gene G-6A polymorphism influences idiopathic pulmonary fibrosis disease progression. European Respiratory Journal. 32(4). 1004–1008. 29 indexed citations
17.
Li, Xiaopeng, et al.. (2008). Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis. American Journal of Physiology-Lung Cellular and Molecular Physiology. 295(1). L178–L185. 153 indexed citations
18.
Uhal, Bruce D. & Amal Abdul‐Hafez. (2008). Angiotensin II in apoptotic lung injury: potential role in meconium aspiration syndrome. Journal of Perinatology. 28(S3). S108–S112. 13 indexed citations
19.
Uhal, Bruce D., Huiying Zhang, Amal Abdul‐Hafez, Ruijie Shu, & Xiaopeng Li. (2006). Amiodarone Induces Angiotensinogen Gene Expression in Lung Alveolar Epithelial Cells through Activation Protein‐1. Basic & Clinical Pharmacology & Toxicology. 100(1). 59–66. 24 indexed citations
20.
Li, Xiaopeng, María Molina‐Molina, Amal Abdul‐Hafez, et al.. (2006). Extravascular sources of lung angiotensin peptide synthesis in idiopathic pulmonary fibrosis. American Journal of Physiology-Lung Cellular and Molecular Physiology. 291(5). L887–L895. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026